Skip to main content
. Author manuscript; available in PMC: 2021 Feb 1.
Published in final edited form as: Lancet Oncol. 2019 Dec 20;21(2):283–293. doi: 10.1016/S1470-2045(19)30797-1

Figure 1. (A-C): Obesity is associated with improved survival outcomes in the TCGA, COMPARZ, and MSK immunotherapy immunotherapy (IO) cohorts.

Figure 1

Unadjusted Kaplan-Meier curves demonstrating differences in OS between normal and obese patients in the (A) TCGA, (B) COMPARZ, and (C) MSK immunotherapy (IO) cohorts. HR=hazard ratio. aHR = adjusted HR. CI=confidence interval. OS=overall survival. TCGA=The Cancer Genome Atlas clear cell kidney cancer. MSK=Memorial Sloan Kettering. NR=not reached.

*TCGA cohort was adjusted for stage and grade. COMPARZ and MSK IO cohorts adjusted for IMDC alone.

^The association of BMI with overall survival in the MSK IO cohort was no longer statistically significant after adjustment for IMDC. No significant association with OS after adjustment for age and sex (aHR 0·60, 95%CI 0·34–1·08).